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 INTRODUCTION 
 
 Psoriasis is a common, genetically determined, inflammatory and 
proliferative disease of the skin.  The most characteristic lesions consist of 
red, scaly, sharply demarcated, indurated plaques present particularly on the 
elbows, knees, lowerback, extensor surfaces and scalp. 
 
 The first recognisable description of psoriasis is attributed to Celsus                  
(25BC-45AD) in his de re medica nearly 2000 years ago.  The disease was 
described under the heading of impetigo from the Latin word impeto which 
means "to attack or rush on" Galen was the first to use the word psoriasis 
from the Greek work 'psora' which means 'to itch'.  Psoriasis and Leprosy 
were grouped together for centuries. Willan was the first to accurately 
describe psoriasis and its various manifestations in 1809, but he did not 
separate it with certainty from Leprosy.  In 1841, Hebra definitively 
distinguished the clinical picture of psoriasis from that of Hansen's disease. 
 
 Eventhough a number of treatment modalities are available, psoriasis 
continues  to be a therapeutic challenge in spite of our growing knowledge 
of its pathogenesis. 
DIFFERENT CLINICAL TYPES OF PSORIASIS 
 
Classical types Psoriasis vulgaris 
Guttate psoriasis  
Pustular psoriasis 
Arthropathic psoriasis  
Erythrodermic psoriasis 
 
Special types Rupioid 
Ostraceous  
Elephantine 
 
Atypical forms Follicular  
Verrucous 
Lichenoid variety  
Linear 
Zonal 
Seborrhoeic 
Mucosal lesions 
Ocular lesions 
 
According to site Scalp 
Penis 
Flexural 
Nail 
Palms and Soles 
 
Palmo plantar psoriasis is one of the type of psoriasis which can occur 
alone or along with the involvement of other areas. 
 
In most cases the lesions are well defined but they are less scaly and 
the surface often shows fissures.  It may be pustular or non pustular 
 
Three forms of lesions can occur in palms and soles 
1. Diffuse hyperkeratotic plaques 
2. Erythematous patches or plaques studded with minute superficial pustules 
3. Discrete scaly plaques or patches 
4. Rarely Rupioid Lesions can occur on the soles with characteristic limpet 
like scales. 
Palmo plantar psoriasis can also be classified as 
1. Pustular   -  Acute pustular bacterid 
    Chronic pustular bacterid 
    Palmo plantar psoriasis with pustules 
2. Non pustular - Diffuse 
    Annular 
    Delling or crateriform 
    Marginal keratotic 
 In this study various topical modalities of treatment are used for 
palmoplantar psoriasis like 
0.1% Betamethasone valerate ointment 
0.05% Tazarotene gel 
Topical PUVA using methoxypsoralen solution 1% 
Short contact compound dithranol oint (dithranol 1.15%, salicyclic acid 
1.15%, coal tar 5.3% in white soft paraffin) 
Liquid paraffin. 
 
There are numerous topical therapies available like coaltar, anthralin, 
methotrexate, vitamin D analogues tacrolimus, salicylic acid 2 - 10%.  
emollients, etc. 
LITERATURE REVIEW 
INTRODUCTION 
 Palmo plantar psoriasis has various therapeutic options both topical 
and systemic.  The topical modalities of treatment generally used are 
1. Coal tar 
2. Dithranol 
3. Topical corticosteroids 
4. Vitamin D analogues 
  a. Calcitriol 
  b. Calcipotriol 
  c. Tacalcitol 
  d. Maxacalcitol 
5. Topical psoralen 
6. Topical retinoid (Tazarotene) 
7. Topical cytostatic therapy 
  a. Mechlorethamine (Nitrogen mustard) 
  b. Thiotepa 
  c. 5 - Flurouracil 
  d. Lomustine 
  e. Methotrexate 
8. Tacrolimus (FK 506) 
9. Emollients 
10. Salicylic acid  2 - 10% 
11. Arachidonic acid 0.5 - 2% 
12. Topical allantoin 
COAL TAR 
 
 Tar has been used in Topical therapy for more than a century 
 
DIFFERENT TYPES OF TAR  [1] 
a. Shale tar 
  Icthammol 
b. Wood tar 
  Juniper tar 
  Pine tar 
  Pix liquida 
c. Coal Tar 
  Coal tar solution 
  Strong coal tar solution 
 
Coal tar is a complex mixture of thousands of substances produced by 
primary condensation during the carbonization of coal[2].  Some 400 known 
substances comprise 55% of Tar by weight. 
 
PREPARATIONS 
 
 Coal tar is available as ointment, liquid, alcohol extract, gel, shampoo 
and soap.  Each has its own used in specific areas.  It is also available in 
combination with salicylic acid. 
 
MECHANISM OF ACTION 
 
1. Anti-Mitotic 
Coal Tar has been found to depress mitosis and DNA synthesis by the 
production of DNA adducts and oxidation induced DNA damage in 
human mammary epithelial cells [3]. 
 
2. Phototoxicity 
Goeckerman in 1925, described the enhancement of the therapeutic 
effect of tar after UV light exposure.  The following components of 
coal tar act as photosensitizers, anthracene, fluoranthrene, 
phenanthrene, benzpyrene and benzacridine [4]. 
Ultraviolet fluorescence microscopy has proved that the hair follicles 
and the sebaceous glands may be an important route of penetration of 
the coal tar into the skin. 
 
3. Sebostatic effect 
It has been found that a 10% coal tar distillate reduces the size of the 
sebaceous glands and the number of mitoses.  It is possible that this 
will lead to a subsequent reduction of the secretion of sebum [4]. 
 
4. Antifungal effect[5] 
It has been demonstrated that coal tar has an antifungal potential on 
Malassezia furfur in vitro.  This could, in part, be responsible for the 
response of seborrhoeic dermatitis and pityriasis capitis to coal tar [5]. 
 
INDICATIONS 
 
Apart from its use in psoriasis, coal tar can also be used in pityriasis 
capitis and seborrhoeic dermatitis [4].  It has also been used in eczemas, 
especially atopic dermatitis [6]. 
 
ADVERSE EFFECTS 
 
 
 Irritation folliculitis and tar acne are the most frequent adverse effects 
of tar treatment.  Phototoxic reactions are also common.  Allergic contact 
dermatitis does occur but is rare. 
 
 
 Kennaway identified two carcinogens in coal tar, 3,4 benzpyrene and                    
1, 2-benzpyrene. A 2.4 fold increased risk of developing skin carcinomas 
was found in patients with high rate of exposure to tar and UV light [7]. 
 
PREPARATIONS 
 
Coal tar is available in the form of ointments, creams, gels, scalp 
shampoos, solutions, lotions and suspensions. 
COMBINATION THERAPIES 
Coal tar can be combined with various other drugs for better efficacy. 
1. Goeckermans regimen [8] 
It consists of daily application of 2 - 5% crude tar, combined with a 
tar bath and UV light.  Many modifications of the Goeckermans 
regimen have been advocated using alcoholic extracts of tar in cream 
or ointment bases, tar gels, etc. which are easier to handle. 
2. Coal  tar and Dithranol [9] 
A combination of 5% crude coal tar and dithranol was found to be as 
effective as dithranol alone when used in short contact treatment of 
psoriasis and was also less irritant. 
3. Coal tar and topical steroids [10] 
This combination reduces the irritation caused by coal tar. 
4. Coal tar and salicylic acid. 
 Used in treatment of psoriasis 
PRECAUTIONS 
1.  Coal tar application should be avoided over face, genitalia and flexures. 
2. Coal tar therapy is contraindicated in erythrodermic and generalised 
pustular psoriasis. 
3. Pre existing folliculities or severe acne are also possible contraindications. 
 
DITHRANOL 
 In history of medicine there are a few accidents proved to be good for 
mankind.  One such is that of dithranol. Chrysarobin, 3-methyl dithranol, 
obtained from araroba tree.  The word araroba meaning ‘tawny coloured’.  
This is the active ingredient of Goa powder, imported by Portuguese from 
Brazil to India [11]. Following misdiagnosis it was accidentally used in 
psoriasis and found to be effective .  It was called "Cignolin" in Germany 
and "Anthraline” in North America. 
 
 
Structural Chemistry [13] 
       OH                        O      HO 
 
 
 
  
 
 
     H  H 
 
Anthralin has an unstable chemistry with 2 focal points: phenolic 
hydroxyl groups at carbon atoms 1 and 8 and two reactive hydrogen atoms 
on carbon ten.  It undergoes auto-oxidation, which is both pH and light 
dependent. 
MECHANISM OF ACTION 
1. Antiproliferative effect 
It induces a decrease in epidermal growth factor binding in a dose 
dependent manner.  This may contribute to the anti psoriatic action of 
dithranol [14] 
Dithranol also causes a marked decrease in transforming growth 
factor α MRNA expression on cultured human keratinocytes [15]. 
 
2. Action of anthralin on mitochondria 
It interacts with the electron transport chain on the inner 
mitochondrial membrane resulting in a reduction of ATP Synthesis [13] 
This loss of energy supply in keratinocytes including reduction of                   
glucose 6 phosphate dehydrogenase could explain, at least in part, the 
therapeutic efficiency of anthralin in psoriasis. 
 
3. Inhibition of biosynthesis  of polyamine by anthralin 
Ornithine decarboxylase catalyses the production of putrescine from 
ornithine and is associated with cellular proliferation.  In psoriatic 
epidermis, polyamine levels are abnormally elevated, so anthralin 
inhibits this polyamine in psoriatic skin [13]. 
4.Effect of anthralin on cyclic nucleotides 
Anthralin has also been shown to reduce the elevated levels of cyclic 
guanosine mono-phosphate (cGMP) that were present in involved 
skin.  Although the precise mechanism is not known, there is much 
evidence to suggest that it acts on various cell regulatory systems [13]. 
5. Anti chemotactic activity of anthralin. 
It is a potent inhibitor of leukotriene production and LTB4 - omega 
oxidation by human neutrophils thereby reducing the LTB4 - induced 
intra epidermal accumulation of polymorphonuclear leucocytes [16]. 
Also significantly lowers IFN - gamma and TNF alpha levels in                      
psoriatic patients [17]. 
Anthralin has been found to cause significant fall in epidermal 
calmodulin levels in the psoriatic lesions associated with clearance of 
psoriatic lesions [18]. 
Anthralin also down regulates 12(S) hydroxy ecosotetraenoic acid                     
(12 (S) HETE) receptors on epidermal cells which may contribute to 
its antipsoriatic action [19]. 
INDICATIONS 
1. Psoriasis - both as monotherapy and in combination with various other 
therapies.  It can also be used in nail and childhood psoriasis. 
2. Facial seborrhoeic dermatitis in low-dose preparations [20].  At higher 
concentrations shown to inhibit growth of pityrosporum ovale [21]. 
3. Inflammatory linear verrucous epidermal naevus [22]. 
4. 2% use in verruca vulgaris [23] 
5. Alopecia  areata [24] 
PREPARATIONS 
 Anthralin is available as paste, ointment, cream and sticks. 
MODIFICATIONS OF ANTHRALIN THERAPY 
1. Short contact therapy [11,12] 
With the hope of avoiding the disadvantages, higher strength of 
dithranol is kept in contact with lesion for a short period.  
Concentrations ranging from 0.5 to 3% and even upto 8% have been 
tried as short contact therapy for 10 -20 minutes and have been found 
to be successful [25]. 
2. Ingram regimen 
First the patient soaks and washes thoroughly in 90 litre (20 gallon) 
bath to which 120 ml of alcoholic solution of coal tar and 30ml of 
teepol is added.  After drying, small doses of UVB are given, 
increasing gradually to suberythmogenic dose.  Then the lesion is 
accurately covered by application of dithranol 0.42% in stiffened 
lassars paste, which is powdered with talc and covered with stockinet 
dressing.  The patient then dresses and pursues his work, returning for 
treatment after 24 hours.  After 24 hours, the paste being removed 
with olive oil prior to bathing the following day [13]. 
Disadvantages of this treatment 
1. Requires hospitalization 
2. Staining of the lesion and dress 
3. Irritation at the site 
3.   Liposomal delivery of dithranol. 
There were no reports of lesional or perilesional irritation and only 
one patient showed faint brown staining of the skin [26]. 
4. Micanol 
 In this dithranol is micro encapsulated in crystalline monoglyceride. 
This preparation is easy to wash off and staining and irritation are 
inconspicuocs.  Hence, it can be used in out patient setting [27]. 
COMBINATION THERAPIES 
 Anthralin can be used in combination with  
 a. PUVA 
 b. Narrowband UVB 
 c. Coal tar 
 d. Topical steroids 
 e. Calcipotriol 
 f. Tazarotene 
 g. Oral cyclosporine 
 h.  Oral retinoids 
 
ADVERSE EFFECTS 
1. Anthralin erythema is due to release of prostaglandin and superoxide 
radicals released from C1O methylene group of anthralin and anthralin 
radicals produced in the skin [28]. 
2. Staining and pigmentation is due to formation of anthraquinone oxidation 
products. 
3. Rarely skin cancer 
4. Ocular damage 
5. Allergic contact dermatitis 
 
PRECAUTIONS 
1. Should be applied only to psoriatic plaques and not to normal skin 
2. Better avoided in face. 
3. Contra-indicated in acute, unstable, generalised  pustular and 
erythodermic psoriasis. 
CONCLUSION 
 Anthralin has been available for many years and has been an useful 
anti-psoriatic agent.  It must be used with care and instructions for its use are 
required for both physicians and patients.  The introduction of short contact 
therapies may make this compound more useful in treatment of palmoplantar 
psoriasis. 
TAZAROTENE 
Tazarotene is a third generation receptor selective polyaromatic, 
synthetic retinoid also known as Arotenoid.  It is a prodrug of a water 
soluble active metabolite called tazarotenic acid.  The conversion takes place 
in the skin by the help of an enzyme called esterase. 
It has high affinity for RAR β γ than for RAR α.  But no affinity for 
RXR. 
 
MECHANISM OF ACTION 
 Down regulates abnormal expression of keratinocyte transglutaminase 
(T gase 1), epidermal growth factor receptor and hyper proliferative keratin 
K6/K16. 
 Blocks the induction of ornithine decarboxylase activity, which is 
associated with cell proliferation and hyperplasia. 
 Inhibits cornified as well as cross linked envelope formation. 
 Decreases migration inhibitory factor related protein (MRP-8) a 
marker of inflammation in psoriasis[29]. 
 Up regulates tazarotene inducible genes (TG 1, 2, 3) and has 
antiproliferative properties 
 
PHARMACO KINETICS 
 Systemic absorbtion is negligible because of rapid metabolism (less 
than 20 minutes) to hydrophilic metabolite and limited percutaneous 
penetration.  Onset of action is within two weeks and elimination half life is 
17 to 18 hrs. 
 Excreted through skin, urine and faeces.  It is available as cream or 
gel (0.05% and 0.1%)  
 
PRECAUTIONS 
 Simultaneous use of tazarotene should be avoided with abrasive or 
medicated soap, products containing high concentration of alcohol, 
astringents, medications or cosmetics having strong drying effects 
 
INDICATIONS 
Mild to moderate psorasis involving 10% - 20% of body surface area[30] 
Acne vulgaris  
Photoaging (Wrinkling, mottled pigmentation, facial roughness) 
Cutaneous T cell lymphoma 
Disorders of keratinization (Dariers disease, pityriasis rubra pilaris, 
ichthyosis) 
Treat and prevent skin cancer (Basal cell carcinoma, Xeroderma 
pigmentosum) [31]  
 
CONTRAINDICATION 
Pregnancy 
Lactation 
 
SIDE EFFECTS 
 Skin irritation, which is characterized by erythema, peeling, 
desquamation, dryness, burning and pruritus[32] 
 Hypo or hyper pigmentation 
 Koebnerization of psoriasis 
 
TOPICAL CORTICOSTEROIDS 
INTRODUCTION 
 The revolution brought about in dermatological therapy by the 
introduction of topical corticosteroids, which started with compound F or 
hydrocortisone in 1952, is well known.  Topical steroids play an important 
role in the treatment of psorasis particularly when combined with other 
modalities of therapy.  
 STRUCTURE 
 
 Hydrocortisone is the parent compound of modern glucocortico 
steroid derivatives.  It has a cyclopentanoperhydrophenanthrene nucleus, 
which has been chemically modified over the years to enhance 
glucocorticosteroid activity and minimise mineralocorticoid effects[33]. 
 Factors affecting the potency of topical corticosteroids are 
lipophilicity of the molecule, additional double bond at 1, 2 position, 
addition of halide at 9, 6, or 21 position and the state of the epidermal 
barrier.  Halogenation of the 9 position will significantly increase 
glucocorticoid activity. 
 
CLASSIFICATION[34] 
 
 The introduction of the vasoconstrictor assay has proved of great 
value in the classification of topical corticosteroids.  The assay depends 
upon the property of corticosteroids to produce transient vasoconstriction.  
Steriod potency can also be assessed by Duhring chamber. 
 
The corticosteroids are classified into the following groups based on 
their potency. 
1. Very potent  : Clobetasol propionate 0.05% 
       Halcinonide 0.5% 
        Beclomethasone dipropionate 0.05% 
2. Potent   : Beclomethasone dipropionate 0.025% 
      Betamethasone valerate 0.1% 
      Fluocinolone acetonide 0.05% 
      Fluocinonide 0.05% 
      Fluticasone propionate 0.05% 
               Momentasone furoate 0.1% 
3. Moderately Potent : Triamcinolone acetonide 0.1% 
               Hydrocortisone butyrate 0.1% 
               Desonide 0.5% 
               Flurandrenolone 0.05% 
4. Mildly Potent  : Clobetasole butyrate 0.05% 
      Fluocortolone hexonate 0.1% 
5. Weak   : Hydrocortisone 0.1 - 2.5% 
      Methyl Prednisolone 0.025% 
 
MECHANISM OF ACTION 
 
 Corticosteroids have anti-inflammatory, immunosuppressive and 
antimitogenic activities due to their ability to exert multiple effects on the 
various functions of leucocytes, epidermal and dermal cells[35]. 
 Corticosteroids diffuse through the stratum corneum barrier and 
through the cell membranes reach the cytoplasm.  In the cytoplasm they bind 
with glucocorticoid receptor α (GRα) and then enters the nuclear 
compartment and interacts with glucocorticoid responsive elements on the 
genome. 
 In addition, the ligand bound receptor can inhibit directly or 
indirectly, the activity of other transcription factors like NFKB, AP-1 and 
NFAT[36]. 
 These interactions leads to suppression of the production of 
inflammatory cytokines, inhibition of T cell activation, changes in the 
function of endothelial cells, granulocytes, mastcells, fibroblast and 
inhibition of proliferation. 
 They induce synthesis of lipocortin that regulate the activity of 
phospholipase A2.  This enzyme affects the production of arachidonic acid, 
the precursor for leukotrienes and prostaglandins[37]. 
 There is one more receptor in the cytoplasm called the GRβ, which is 
an endogenous inhibitor of glucocorticoid action[38].  Staphylococcal 
superantigen can upregulate expression of GRβ, providing a potential 
mechanism by which these bacteria might induce corticosteroid 
resistance[39]. 
THERAPEUTIC USES 
 
Papulosquamous  disorder. 
  1. Psoriasis 
  2. Lichen planus[40] 
  3. Reiters disease 
 
Eczemas 
  1. Atopic dermatitis[41] 
  2. Seborrhoeic dermatitis[42] 
  3. Contact dermatitis (allergic, irritant) [43] 
  4. Photocontact dermatitis 
  5. Lichen simplex chronicus 
  6. Actinic reticuloid[43] 
  7. Pompholyx[42] 
  8. Asteatotic eczema 
 
 
Bullous disorders 
  1. Pemphigus group[43] 
  2. Bullous pemphigoid[46] 
  3. Epidermolysis bullosa 
  4. Sub corneal pustular dermatosis 
Collagen vascular diseases 
  1. Lupus erythematosus 
  2. Dermatomyositis 
Miscellaneous 
  1. Alopecia areata 
  2. Hemangiomas 
  3. Mycosis fungoides[44] 
  4. Sarcoidosis 
  5. Vitiligo 
  6. Cutaneous amyloidosis 
  7. Keloid / Hypertrophic scar 
  8. Aphthous stomatitis 
  9. Mastocytosis and Urticaria pigmentosa 
  10. Acne rosacea 
  11. Vasculitis, etc. 
PREPARATIONS 
  
They are available as ointments, creams, lotions, gels, foams, sprays 
and tapes[46]. 
 
COMBINATION THERAPIES 
 
 Topical corticosteroids have been used in combination with various 
other topical and systemic agents in the treatment of psoriasis.  They are 
1. Coal tar[47] 
2. Anthralin 
3. Calcipotriol[48] 
4. Tazarotene[49] 
5. PUVA[50] 
  
ADVERSE EFFECTS 
 
 
Epidermal  : Thinning of epidermis 
       Reduction in the size of epidermal cells 
       Reduction in the metabolic activity 
       Reduction in the number of cell layers 
Inhibition of melanocyte function with 
hypopigmentation 
 
 
 
Dermal : Resorption of mucopolysaccharide ground 
substance with atrophy[51] 
 
      Fragility of skin 
      Suppression of collagen synthesis, so striae 
 
 
Vasculature  :  Loss of connective tissue support  leading to 
      Erythema 
       Telangiectasia[52] 
      Purpura 
 
Miscellaneous 
    Perioral dermatitis[52] 
    Acneiform eruption 
    Acne rosacea 
    Glaucoma 
    Cataracts and retinal detachment[53] 
    Allergic contact dermatitis[54] 
    Hypertrichosis 
    Infantile gluteal granulomas 
    Delayed wound healing 
    Cutaneous lymphangiectases[55] 
    Tachyphylaxis. 
 
SYSTEMIC 
 Suppression of the pitutary - adrenal axis can occur with virtually any 
topical steroid especially potent steroids, leading to cushing syndrome[56] 
 
PRECAUTIONS 
No more than 45 gm per week of moderate to potent steroids in adults 
and 15gm per week in young children and infants are recommended for 
topical use. 
Corticosteroids on continued use exhibit tachyphylaxis, the 
development of acute tolerance. 
Sudden withdrawal of topical steroids in psoriasis can precipitate 
pustular psoriasis. 
Topical steroids are to be used with caution over the face. 
 
CONCLUSION 
  
 Topical steroids play an important role in the treatment of psoriasis.  
They should be used judiciously because of the possibility of rebound 
phenomenon when they are discontinued as well as the potential 
development of topical and systemic adverse effects.  They can play an 
important role as an adjunct to other forms of therapy in the treatment of 
psoriasis. 
  
SALICYLIC ACID 
 
INTRODUCTION 
 
 Willow bark  (Salix alba) is an ancient herbal remedy.  The chemical 
structure of its active ingredient, salicylic acid (2-hydroxy-benzoic acid) was 
identified in 1838 [57] 
 
Salicylic acid is a crystalline powder.  It is lipid soluble and hence 
miscible with epidermal lipids and sebaceous gland lipids. 
To obtain significant keratolytic effect salicylic acid must be 
formulated at a proper pH so that there will be enough of  free acid. 
STRUCTURE 
             COOH 
 
 
        OH 
 
 
 
MECHANISM OF ACTION 
 
 Reduction of corneocyte adhesion, perhaps by an action on the cement 
substance.  This results in enhanced shedding of corneocytes and has no 
effect on mitotic activity[58]. 
Topical Salicylic Acid 
 
Corneocytes 
desquamate 
  
 Corneocyte       pH of Stratum 
  Intercellular bonding     Corneum 
    
    Corneocytes 
    swell and soften  Hydration 
 Salicylic acid thus can cause enhancement of penetration of other 
chemicals like topical corticosteroids. 
 
Salicylic acid can be photoprotective[59]. 
 
It also has bacteriostatic and bactericidal activity against yeast, gram 
negative and gram positive bacteria[57] 
INDICATIONS 
Psoriasis[60] 
Seborrhoeic dermatitis[58] 
Ichthiosis[58] 
Warts[61] 
Corns and calluses[58] 
Acne[58] 
Pityriasis rubra pilaris[62] 
Keratodermas[58] 
Dermatophyte infections[58] 
Avulsion of toe nails[58] 
Sunscreens[63] 
Alopecia[64] 
PREPARATIONS 
 
Salicylic acid is available in 
 
Collodion - based paints and gels 
Shampoos 
Ointments 
Paste (Lassars paste contains salicylic acid and zinc oxide) 
Creams 
COMBINATION THERAPIES 
 
Salicylic acid is used commonly in combination with various other 
topical therapeutic agents like,  
Corticosteroids[65] 
Coal tar 
Other Keratolytics  Lactic acid 
    Propylene glycol 
    Urea[66] 
Sulphur 
Benzoic acid  ( Whitfield ointment) 
Zinc oxide (Lassars paste) 
Anthralin ( Salicylic acid prevents the oxidation of anthralin) 
Calcipotriol[67] 
 ADVERSE EFFECTS 
 
Irritation and maceration at high concentrations 
Contact sensitization 
Systemic toxicity (Salicylism) [68] 
     The manifestations include nausea, vomiting, confusion, dizziness, 
delerium, psychosis, stupor, coma and death.  Can also cause marked hyper 
ventilation and respiratory alkalosis. 
 
 
PRECAUTIONS 
 
 
Increases the toxicity of other topical agents because of enhanced 
absorption and hence should be used with caution. 
Prolonged use should be avoided to prevent salicylism. 
Used with caution in patients with hepatic and renal impairment 
especially young children. 
It blocks UVB and inactivates calcipotriol if used concurrently[69]. 
 
 
 
CONCLUSION 
 
 Salicylic acid, especially when used cautiously, is an effective and 
safe antipsoriatic agent. 
 
TOPICAL PUVA THERAPY 
 
 Psoralen photochemotherapy is a combination of psoralen (P) and 
long wave UVR (PUVA) that brings about a therapeutically beneficial result 
not produced by either the drug or radiation alone [70,71]. 
 Application of 8-MOP in creams, ointments or lotions followed by 
UVR is effective in clearing psoriasis but has several disadvantages. 
PSORALEN PHOTO CHEMISTRY 
 
 Ground state psoralen molecules are activated to the excited singlet 
state by absorption of photons in the UVA wave band.  The peak of the 
absorption spectrum is around 320 – 330 nm.  Two types of photo chemical 
reaction occur[72].  
 
 Type 1 – (Direct) resulting in mono functional adducts in DNA 
strands. 
 
  
Type-2 – (Indirect) reactions resulting in production of reactive O2 
species and free-radicals that cause damage to cell membrane and 
cytoplasmic constituents[73].   
 
 
MECHANISM OF ACTION 
 
Suppersion of DNA Synthesis, through formation of mono and bi 
functional adducts [74], which occurs immediately.  Subsequently cell 
proliferation is also inhibited in patients with psoriasis who receive repeated 
PUVA treatment. 
 
IMMUNOLOGIC EFFECTS 
 
 PUVA down regulate certain lymphocytes and antigen presenting 
cells and influences adhesion molecule expression [75]. 
 
 Selective cytotoxicity through production of free radicals  
 
 Stimulation of melanocyte proliferation and increased tyrosinase 
synthesis. 
 
 
 
 
INDICATIONS [76-79] 
 Psoriasis[80,81] 
 Vitiligo 
 Mycosis fungoides 
Lymphomatoid papulosis 
Pityriasis lichenoides 
Langerhans cell histiocytosis 
Atopic dermatitis[82] 
Seborrhoeic dermatitis 
Pityriasis rubra pilaris 
Lichen nitidus 
Alopecia areata 
Urticaria pigmentosa 
Actinic prurigo[83] 
 
MODE OF ADMINISTRATION 
 
 
 Applied in the form of lotion and creams.  A lotion containing 0.1 to 
1.0 % 8 methoxypsoralen is used.  Then the area should be exposed to UVA.  
This treatment is given twice weekly with UVA dose being gradually 
increased.   
 The hands should be immediately washed and topical emollients 
should be applied and further photo protection from sunlight insisted using 
sun screeners. 
 
LIGHT SOURCES FOR UVA 
 
 UVA radiation spectrum ranges from 320 to 400 nm.  The PUVA 
action spectrum is defined as the effectiveness of clearing psoralen 
sensitized psoriasis as a function of wave length.  Currently broad band high 
intensity UVA sources ranging from 320 to 400 nm with a peak emission at 
352 nm are typically used in PUVA. 
 
 However recent advances demonstrate the peak action spectrum of 
psoriasis to be around 330 nm.   
 
 The commonly used lamps are [84] 
1. Fluorescent lamps  
2. Metal halide lamps 
 
 
PHOTO SENSITIVE EFFECTS OF PUVA 
 
PUVA produces an inflammatory response that manifest as  
1. Delayed phototoxic erythema [85,86] 
2. Intense pruritus 
3. Pigmentation 
These reactions are related to the dose of the drug and of UVA and to 
the individual sensitivity to phototoxic reaction. 
 
TREATMENT PROCEDURE 
 Before starting a patient on PUVA therapy contra indication to it have 
to be excluded. 
 
CONTRA INDICATION [87] 
 
ABSOLUTE 
1. Xeroderma pigmentosum, Blooms syndrome and other congenital 
photo sensitivity disorders  
2. Lupus erythematosus  
3. Pemphigus, pemphigoid [88] 
4. History of idiosyncratic reaction to psoralen compounds 
RELATIVE 
1. Concurrent photo sensitizing medication 
2. Prior exposure to ionizing radiation or arsenic[89] 
3. History of skin cancer/chronic actinic damage[89] 
4. History or family history or melanomas 
5. Pregnancy, lactation [90] 
6. Age less than 18 years 
7. Significant renal, hepatic or cardiac disfunction 
8. Cataract 
 
ADVERSE EFFECT[77] 
 
 
SHORT TERM 
 
A. Photo toxic reactions 
1. Erythema 
2. Pruritus 
3. Pain 
4. Blistering on hands and feet 
5. Photonycholysis 
6. Phytophoto dermatitis 
 
B. Due to psoralen 
1. Nausea, vomiting 
2. Head ache 
3. Dizziness 
4. Broncho constriction 
5. Hepato toxictity 
6. Drug fever 
7. Exanthems 
 
C. Unsual side effect 
1. Hypertrichosis of face 
2. Subungual haemorrhage of finger nails 
3. Acneiform eruptions 
4. Induction of bullous pemphigoid 
 
LONG TERM ADVERSE EFFECT 
1. Chronic actinic damage 
2. Carcinogenesis – Squamous cell carcinoma [91,92] 
         - Melanomas 
 3.   Cataract  
 4.   Immunological 
 
Advantages 
 
 No systemic side effects such as nausea and no carcinogenic effects. 
Disadvantages 
1. Topical PUVA is laborious and time consuming if every lesion has 
to be treated individually 
2. The formation of erythema and blisters is more common with 
topical psoralen application 
3. Intense irregular pigmentation may be seen at the site of treated 
plaques 
AIM OF THE STUDY 
 
BACKGROUND 
 
 Palmoplantar psoriasis  is a chronic disease with remissions and 
exacerbations.  Most of the topical therapies currently available for psoriasis 
are either suited for short term therapy or long term maintenance therapy.  
Furthermore topical corticosteroids commonly used for palmplantar 
psoriasis, show diminished response on continuous use due to tachypylaxis 
and more incidence of recurrence. 
 
 
OBJECTIVE 
 
 To compare the efficacy of various topical therapies like 
 
Short contact compound dithranol ointment (dithranol 1.15%, salicylic acid 
1.15%, coal tar solution 5.3% in white soft paraffin) 
Topical 0.1% Betamethasone valerate ointment 
Topical tazarotene 0.05% gel 
Topical PUVA using -1% methoxypsoralen solution 
Liquid paraffin. 
 MATERIALS AND METHODS 
 
 
100 patients who attended the psoriasis out patient clinic at the 
department of Dermatology, Government General Hospital, Chennai from 
September 2004 to September 2006 were included in the study.   The 
diagnosis was made on clinical grounds and histopathological examination. 
 
INCLUSION CRITERIA 
 
Patients with stable palmoplantar psoriasis 
Patients who has not used other forms of topical therapy during the previous 
4 weeks. 
For topical PUVA therapy age more than 18years was considered. 
 
EXCLUSION CRITERIA 
 
Palmoplantar psoriasis along with other body surface area involvement. 
Pregnancy and lactation 
Unwillingness to give consent for return for weekly evaluation. 
Patients who have had other forms of therapy during the previous 4 weeks. 
 PATIENT EVALUATION  
History 
General Examination 
Systemic Examination 
Dermatological Examination 
Laboratory Investigations 
 a. Baseline Haemogram 
 b. Urinary Analysis 
 c. Biopsy in doubtful cases 
 
TREATMENT PROTOCOL  
 
 100 patients were randomly allocated to 5 groups (20 patients each) to 
receive topical 0.1% betamethasone valerate, 0.05% tazarotene, short 
contact compound dithranol, topical PUVA and liquid paraffin respectively. 
Topical 0.1% betamethasone valerate was applied twice daily. 
0.05% tazarotene was applied once a day at bed time. 
Short contact compound dithranol was used for 20 minutes once a day. 
Topical PUVA was given thrice weekly after applying 1% methoxypsoralen. 
Liquid paraffin was used three times daily. 
TREATMENT EVALUATION 
 
 Severity and extent of psoriasis were evaluated at pretreatment 
baseline (Day 0) and then at weekly intervals for 4 weeks, followed 
fortnightly for 12 weeks, followed by monthly intervals up to 24 weeks by 
means of "Psoriasis Area and Severity Index" (PASI). 
Severity of erythema (E), Desquamation (D) and Induration (I) was 
recorded on a 5-point scale as follows 
 
0 - Nil 
1 - Mild 
2 - Moderate 
3 - Severe 
4 - Very severe 
 
Area of involvement for palms and soles was taken as 1 i.e less than 10% 
involvement 
PASI was calculated as 
 PASI  =  0.2 (EU + IU + DU) AU + 0.4 (EL + IL + DL) AL 
 U - Palms (Upperlimb) 
 L - Soles (Lower limb) 
At each weekly visit, the patients were asked about complaints and 
adverse effects like itching or burning sensation in lesional or perilesional 
skin.  Patients were also examined for perilesional erythema. 
 
OBSERVATIONS AND RESULTS 
 
 
AGE DISTRIBUTION 
 
 The mean age in this study was 43.35.  The range was from 10 to 85 
years.  The age distribution is depicted in Fig.1 
 
SEX DISTRIBUTION 
 
In patients chosen for steroids and dithranol, the males and females 
were equal, where as for placebo and tazarotene males outnumbered females 
and for PUVA, females outnumbered males. (Fig. 2)  
The overall male to female ratio was 52 :48. (Fig. 3) 
 
DURATION OF ILLNESS 
 
 The mean duration of psoriasis among the patients was in the range 
between 39.11 and  25.65 months. (Fig. 4) 
 
EXACERBATING FACTORS 
 
 There was no exacerbating factor for 86% of the study group.  Among 
the most common exacerbating factor, stress, cold and menopause, 9% was 
for stress and 3% & 2% was for cold and menopause respectively. (Fig. 5) 
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Fig. 6 PERCENTAGE OF NAIL INVOLVEMENT
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FAMILY HISTORY 
 
 Family history of psoriasis was present among 3% of total patients, 
1% each in placebo, tazarotene, dithranol groups and none in the PUVA and 
steroid groups.  
 
NAIL CHANGES 
 
 46% had no nail changes. Among the others 23% had ridging, 21% 
had pitting, 3% had onycholysis, 4% pitting and ridging and 3% had 
onycholysis and ridging. (Fig. 6) 
 
FOCAL SEPSIS 
 17% had evidence of focal sepsis in the ear, nose and throat and dental 
sepsis in the form of gingivitis, which was treated before the onset of 
therapy.   
 
PASI REDUCTION 
 Fig. 7 depicts the reduction in the PASI scores obtained in the 5 
groups at 0,4,8,12 and 24 weeks. 
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 From the graph, the mean baseline PASI scores in the PUVA, steroid, 
tazarotene, placebo and dithranol were 3.3, 3.2, 3.3, 3.1 and 3.2 respectively.  
At 4 weeks of treatment, the mean PASI scores in 5 groups were 2.6, 2.8, 
2.8, 2.6 and 2.7 respectively.  At the end of 6th and 12th week there was 
substantial reduction in the mean PASI scores for all the groups.   In the 
steroid group there was increase in PASI score between 4th and 6th week and 
thereafter reduction was observed up to the end of 24th week.   At the end of 
24th week the tazarotene and PUVA groups showed a sustained reduction in 
PASI score to 0.51 & 0.69 respectively.   The other three groups showed a 
moderate reduction in PASI score between 1.14 and 1.67. 
 
PERCENTAGE REDUCTION IN PASI 
 Fig. 8 depicts the percentage reduction in PASI scores in all the 5 
groups at 4,8, 12 & 24th  week.  At the end of 24th week there was 84.66% 
reduction in PASI for tazarotene group followed by PUVA with 79.17%, 
dithranol with 63.46%, steroid with 55.38% and placebo with 46.94%. 
 
ADVERSE EFFECTS 
 Adverse effects were found in all the groups except placebo.  During 
4th to 6th week of treatment, 25% of patients in steroid group showed 
exacerbation in the form of erythema.  15% of patients in tazarotene group 
showed in the form of dryness and pruritus.  15% of patients of PUVA group 
showed in the form of erythema, polymorphic light eruption, burning 
sensation.  15% of patients in dithranol group showed in the form of burning 
sensation and pigmentation. 
 
TOPICAL TAZAROTENE GROUP 
 
Before therapy 
 
The same patient after 12 weeks of treatment  
TOPICAL TAZAROTENE GROUP 
 
Before therapy 
 
The same patient after 24 weeks of treatment 
TOPICAL PUVA GROUP 
 
Before therapy 
 
The same patient after 12 weeks of treatment 
 
TOPICAL PUVA GROUP 
 
Before therapy 
 
The same patient after 24 weeks of treatment 
 
TOPICAL DITHRANOL GROUP 
 
Before therapy 
 
The same patient after 24 weeks of treatment 
 
TOPICAL DITHRANOL GROUP 
 
Before therapy 
 
The same patient after 24 weeks of treatment 
TOPICAL STEROID GROUP 
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TOPICAL STEROID GROUP 
 
Before therapy 
 
The same patient after 24 weeks of treatment 
TOPICAL LIQUID PARAFFIN GROUP 
 
Before therapy 
 
The same patient after 12 weeks of treatment 
ADVERSE EFFECTS 
 
Erythema after PUVA therapy 
 
Pigmentation after dithranol therapy 
DISCUSSION 
 
 The study has shown that the mean age of the patients was 43.35 
ranging from 10 to 85 years.  The sex ratio was 52% male and 48% female.  
The various exacerbating factors in this study in descending order were 
stress, cold weather and menopause.  Topical therapies like short contact 
compound dithranol, 0.1 % Betamethasone valerate, topical PUVA, 0.05 % 
tazarotene and liquid paraffin were used and reduction in PASI was assessed 
at every 4th , 6th , 12th  & 24th weeks.  
 
TAZAROTENE GROUP 
 Previous study on the topic “Management of topical modalities of 
psoriasis with special reference to Tazarotene by Dr.Susmit Haldar reported 
50% of improvement by applying Tazarotene gel 0.05% twice daily at the 
end of 6weeks[30]. 
In this study, treatment made with the same 0.05% of Tazarotene gel 
once a day showed a maximum percentage reduction in PASI at the end of 
8th, 12th and 24th week was 34.14%, 64.81% and 84.66% respectively.  
Maximum improvement was observed between 12th and 24th week. 
There was excellent compliance among the patients in this group and 
there were no defaulters.  Patients also had minimal adverse effects like 
irritation, erythema, dryness and pruritus. 
 
PUVA GROUP (TOPICAL) 
 In this study PUVA group showed the second best efficacy after 
tazarotene group showing a maximum reduction in PASI 79.17% at the end 
of 24 weeks as evidenced by flattening of plaques, decreased scaling and 
erythema[80,81].  This was consistent with the previous study conducted with 
topical application of methoxypsoralen plus UVA in which 67% of patients 
responded with considerable improvement. 
15% of the patient had adverse effects in the form of polymorphic 
light eruption, erythema and burning sensation at the exposed areas.  Except 
4 defaulters, there was good compliance among the patients.  
 
DITHRANOL GROUP 
 In this group, the percentage improvement in PASI was found to be 
63.46% at the end of 24 weeks[12].   
The study was consistent with the study conducted in UK by         
Gisslen H, Nordin P in which complete clearance of lesions was reported in 
75% of the patients at the end of 24 weeks.  
There was also good compliance in this group with no defaulters, 
however some adverse effects in the form of burning sensation and 
pigmentation were seen.  However when the contact period was reduced to 
10minutes the adverse effects reduced significantly 
STEROID GROUP (0.1% BETAMETHASONE VALERATE GROUP) 
 
 Steroid group showed moderate efficacy with 55.38% improvement in 
PASI at the end of 24 weeks.  However, there was no specific study reported 
using 0.1% betamethasonevalerate. There was good compliance among the 
patients with no defaulters.  Few side effects like erythema and exacerbation 
were observed  in some patients. 
 
PLACEBO GROUP (LIQUID PARAFFIN) 
 
 In this group application of liquid paraffin showed 46.94% reduction 
of PASI at the end of 24weeks. There was good compliance among this 
group with no defaulters and no adverse effects.  
The previous study has reported that use of liquid paraffin in palmo 
plantar psoriasis relieved feeling of dryness and pruritus[93].  There was no 
specific improvement or deterioration of the disease. 
 
 
 
 
CONCLUSION 
 
 Topical therapies are the first line therapeutic strategy in the treatment 
of localized palmoplantar psoriasis and can be made effective when the 
appropriate drugs were used judiciously. 
 Among the five modalities compared in this study, tazarotene (0.05%) 
gel may be considered as an initial treatment of choice. 
 Topical PUVA is as effective as tazarotene except for the limiting 
factors for PUVA therapy such as availability of PUVA unit, patient 
compliance and long term side effects.    
 Topical dithranol is as effective as topical PUVA when used as 
20minutes short contact therapy. 
 Topical 0.1% Betamethasone valerate was moderately effective with 
frequent exacerbation.    
Liquid paraffin was the least effective with no adverse effects, no 
exacerbation and remissions.  However it can be used as an adjunct with 
other topical therapies. 
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COMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL 
TREATMENT MODALITIES IN PALMOPLANTAR PSORIASIS 
PROFORMA 
 
Date 
 
Name:      Age:  Sex: 
Address: 
 
 
Case No:      Psoriasis clinic no: 
Marital Status:      Occupation: 
 
History 
 
Duration   Years   Months 
 
Itching    Yes   No 
 
 
Exacerbation with 
 
 Cold Climate   Sunlight   Dialysis 
 
 Infection   Trauma   Mental stress 
 
 Puberty   Pregnancy   Menopause 
 
 Drugs 
 
• Preceding sore throat  Yes    No 
• Alcohol intake   Yes    No 
• Systemic illness  Diabetes   Hypertension    HIV 
• Pregnancy   Yes    No 
• Lactation   Yes    No 
• Past history of  Photosensitivity  Cutaneous malignancies 
• Family history of Psoriasis  Mother   Father 
Sibilings   Others 
• Number of Children   Male    Female
 Drug Intake 
 
 Lithium   NSAIDS   Natural remedies 
 
 Steroid withdrawal  Beta blockers  Antimalarials 
 
 Amiodarone   Digoxin   Trazadone 
 
 Penicillin   Terfenadine 
    
     
 
Examination 
 
General 
 
Systemic:  CVS  RS  Abdomen  CNS 
 
Dermatological 
 
Auspitz sign   No   Yes 
 
Clinical type   Palmoplantar 
 
Nail changes   None  Pitting   Onycolysis 
 
    Subungual hyperkeratosis  Ridges 
   
 
Joint involvement  Yes     No 
 
Focal sepsis   ENT  Dental   Others 
 
Surface area involved  
 
 
Investigations Hb:  TC:  DC:  ESR: 
 
   Urine albumin:  Sugar:  Deposits: 
   Blood sugar:   Urea:  Creat: 
   Sr.Calcium:   LFT:  VDRL: 
   Biopsy      ELISA 
Follow up 
 
UPPER LIMB 
PALMS 
LOWER LIMB 
SOLES Date 
No 
of 
Wks E I D A E I D A 
PASI 
SCORE 
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
 
E – Erythema, I – Induration, D – Desquamation, A – Area,  
 
PASI – Psoriasis Area and Severity Index 
Erythema / Induration / Desquamation scoring Area Scoring for Palms & Soles  
 
 
0 – Nil       0 – Nil      
 
1 – Mild      1 – Less than 10% 
 
2 – Moderate 
 
3 – Severe 
 
4 – Very severe 
 
 
PASI SCORE = 0.2 (EH + IH+ DH) AU + 0.4 (EH + IH+ DH) AL 
MASTER CHART 
S.NO AGE SEX DU EX FH NI FS GR PASI-0 PASI-4 PASI-8 PASI-12 PASI-24 AE 
1 44 M 1 N N P Y TAZ 3.40 2.40 1.40 0.80 0.00 N 
2 42 F 1 N N R N TAZ 4.40 4.60 3.60 2.60 1.60 N 
3 63 F 0.5 ST N N Y TAZ 2.60 2.60 2.80 1.40 0.80 N 
4 62 M 0.58 N N N N TAZ 3.00 2.20 1.80 0.80 0.00 N 
5 29 F 3 ST N R N TAZ 2.60 3.40 2.20 0.60 0.00 Y 
6 10 M 2 N N N N TAZ 4.00 3.00 1.80 1.60 1.20 N 
7 38 M 4 N N P Y TAZ 2.40 3.00 3.20 1.60 0.80 N 
8 55 M 3 N N N N TAZ 3.60 3.80 2.40 1.20 0.80 N 
9 68 M 10 N N P N TAZ 3.20 2.60 2.00 0.80 0.60 Y 
10 35 M 4 N N N N TAZ 4.60 2.80 2.20 1.00 0.40 N 
11 28 M 2 N N O N TAZ 2.00 1.00 0.60 0.00 0.00 N 
12 58 F 1 M N P N TAZ 3.50 3.30 3.00 1.60 0.60 N 
13 49 M 2 N N R N TAZ 4.00 3.00 2.80 1.00 0.00 N 
14 65 F 0.5 N N N N TAZ 2.20 1.40 1.20 0.60 0.00 N 
15 50 F 1 N N P,R Y TAZ 3.40 2.80 2.20 1.00 0.80 Y 
16 32 F 1.5 N N N N TAZ 3.20 2.20 1.60 1.00 0.00 N 
17 27 M 0.67 N N P N TAZ 3.20 2.60 1.60 0.60 0.00 N 
18 62 F 1 ST N P,R N TAZ 3.80 3.20 2.60 1.40 0.60 N 
19 41 F 2 ST N N N TAZ 4.60 4.00 2.80 2.00 0.60 N 
20 10 M 2 N Y R N TAZ 2.80 2.60 2.00 1.80 1.40 N 
  43.4   2.138         TAZ 3.33 2.83 2.19 1.17 0.51   
21 14 F 0.58 N N R N PLA 2.60 1.80 1.40 0.60 0.20 N 
22 68 F 0.08 N N O N PLA 2.80 1.80 2.00 1.60 2.20 N 
23 53 M 0.5 N N N N PLA 1.80 1.60 2.00 2.40 1.80 N 
24 38 M 0.75 N N N N PLA 3.80 2.20 1.80 2.00 2.40 N 
25 63 M 15 ST Y R N PLA 2.80 2.60 2.00 1.60 1.40 N 
26 47 M 0.25 N N P N PLA 3.60 2.80 2.40 2.00 1.80 N 
27 40 M 4 N N N N PLA 2.60 2.40 2.20 2.60 1.80 N 
28 23 M 13 N N P N PLA 4.80 4.40 3.60 3.20 3.40 N 
29 30 M 3 CO N N N PLA 4.00 3.60 2.80 2.00 1.80 N 
30 13 F 2 N N R Y PLA 2.00 1.80 1.40 0.80 0.40 N 
31 36 M 0.25 N N N N PLA 2.60 2.00 1.80 0.60 0.20 N 
32 49 F 0.67 N N O,R N PLA 3.20 2.60 2.00 1.40 0.80 N 
33 51 M 2 N N N N PLA 2.80 2.60 2.80 2.20 2.60 N 
34 13 M 1.5 N N N N PLA 3.20 2.20 1.60 1.47 0.80 N 
35 50 F 5 N N P N PLA 4.80 4.60 3.80 4.20 4.00 N 
36 85 F 0.5 N N N N PLA 3.60 3.40 3.00 2.80 2.60 N 
37 12 M 3 N N P Y PLA 2.60 2.20 1.60 0.80 0.80 N 
38 32 M 0.5 N N N N PLA 2.60 2.00 2.20 1.80 0.80 N 
39 58 F 2 N N R N PLA 4..8 3.60 3.20 2.40 2.00 N 
40 60 F 1 N N R N PLA 3.60 3.20 2.60 2.00 1.60 N 
  41.75   2.779         PLA 3.15 2.67 2.31 1.924 1.67   
41 18 F 10 N N P N PUV 4.80 4.00 3.40 2.60 1.80 N 
42 48 F 0.83 N N P N PUV 2.80 2.00 1.60 1.20 0.80 N 
43 31 F 3 N N N Y PUV 1.80 1.60 0.60 0.60 0.40 N 
44 35 F 0.17 N N P N PUV 2.80 2.20 1.80 - - Y 
45 60 F 0.5 N N N Y PUV 4.20 3.20 2.80 1.80 0.80 N 
46 45 M 20 N N O N PUV 4.80 3.80 2.60 2.00 1.20 Y 
47 37 F 3 N N R N PUV 3.20 2.80 2.20 1.40 0.80 N 
48 38 M 2 N N R N PUV 4.80 4.00 - - - - 
49 60 F 0.25 ST N R N PUV 3.00 2.80 1.80 1.20 0.60 N 
50 42 F 1 N N N N PUV 4.80 3.60 2.80 1.60 0.80 N 
MASTER CHART 
51 40 M 0.5 N N R N PUV 2.20 2.20 1.20 0.80 0.20 N 
52 50 M 3 N N N N PUV 2.80 2.00 1.60 1.20 0.60 N 
53 50 M 0.42 N N R Y PUV 2.60 2.40 - - - N 
54 34 F 3 CO N N N PUV 2.80 2.00 1.40 0.80 0.00 N 
55 52 M 0.5 N N N N PUV 3.20 2.40 1.80 1.40 0.80 - 
56 39 F 4 N N R N PUV 2.00 1.80 1.40 - - Y 
57 40 M 3 ST N N N PUV 2.60 2.20 1.60 0.80 0.60 N 
58 28 F 1.5 N N P,R N PUV 4.20 3.60 2.20 1.40 0.80 N 
59 28 M 4 N N N N PUV 2.80 1.60 1.00 0.80 0.40 N 
60 42 M 4.5 N N N N PUV 3.80 2.60 2.00 1.80 0.40 N 
  40.85   3.259         PUV 3.30 2.64 1.878 1.338 0.688   
61 63 F 5 N N P N STE 3.40 3.00 3.20 1.20 1.00 N 
62 45 F 2 ST N N N STE 2.20 1.60 1.80 0.80 0.80 N 
63 30 M 3 N N R N STE 3.20 2.60 2.40 0.80 0.80 N 
64 62 M 3 N N N N STE 3.40 2.40 2.60 1.00 0.80 N 
65 50 F 0.83 N N R N STE 4.40 4.00 3.60 2.80 2.40 Y 
66 42 F 2 N N N N STE 3.20 3.00 3.20 1.80 1.40 N 
67 49 M 0.75 N N N Y STE 3.20 2.40 2.80 3.20 2.40 Y 
68 68 F 1 N N P N STE 2.60 2.40 2.60 1.00 0.80 N 
69 37 M 1 N N R N STE 2.80 3.00 3.20 2.20 1.80 N 
70 65 F 2 N N P,R N STE 3.80 3.60 3.60 3.20 2.40 Y 
71 25 F 6 N N N N STE 2.60 2.40 2.60 1.00 0.80 Y 
72 62 F 5 N N R N STE 4.40 4.00 3.80 2.00 1.80 N 
73 61 M 1 N N N N STE 3.80 3.40 3.00 2.00 1.80 N 
74 50 M 3 N N P N STE 4.00 3.20 3.40 1.60 1.00 Y 
75 45 F 0.5 CO N R N STE 2.20 2.00 2.20 0.80 1.20 N 
76 48 M 0.5 N N N N STE 2.80 2.40 2.60 1.00 0.80 N 
77 38 F 0.5 N N N Y STE 3.80 3.20 3.20 1.80 1.20 N 
78 43 M 1 N N N N STE 2.60 2.20 2.40 1.20 1.00 N 
79 47 M 20 N N R N STE 4.60 3.80 4.00 4.40 3.60 N 
80 60 M 0.25 N N N N STE 2.00 1.80 2.20 1.20 1.20 N 
  49.5   2.917         STE 3.25 2.82 2.92 1.75 1.45   
81 43 M 5 N N P N DIT 3.20 3.00 2.40 1.40 1.60 N 
82 47 M 1.5 N N N N DIT 4.40 3.60 2.60 1.40 0.60 N 
83 23 F 3 N N N Y DIT 3.60 3.00 1.80 2.20 1.60 N 
84 13 F 1 N Y P Y DIT 2.40 3.00 3.20 1.60 0.80 N 
85 30 F 0.67 N N N N DIT 4.60 3.80 2.40 1.40 0.80 N 
86 36 M 0.17 N N N Y DIT 2.00 1.00 0.60 0.00 0.00 N 
87 59 M 1 N N N N DIT 1.80 1.60 0.60 0.60 0.60 N 
88 36 F 2 ST N O,R N DIT 1.80 1.60 0.60 0.40 0.00 N 
89 46 M 2 N N N Y DIT 2.60 3.40 2.80 2.00 0.60 N 
90 18 M 1 N N N Y DIT 2.40 1.40 1.20 1.60 1.80 N 
91 65 F 0.58 N N R N DIT 4.00 3.00 1.80 1.60 1.20 N 
92 67 F 3 N N N N DIT 2.60 3.40 2.20 0.60 0.40 Y 
93 34 F 3 N N R N DIT 4.40 4.60 3.80 2.40 1.60 Y 
94 21 M 0.42 N N N N DIT 2.00 1.00 1.60 1.40 0.00 N 
95 30 F 2 N N P N DIT 4.00 3.00 1.80 1.60 1.20 N 
96 28 M 3 N N P N DIT 2.20 1.60 1.40 1.20 1.20 N 
97 52 M 6 N N P N DIT 4.40 3.80 3.60 2.60 2.20 N 
98 65 M 4 N N N N DIT 2.60 2.50 2.00 1.60 1.40 Y 
99 60 F 7 M N P Y DIT 4.80 4.60 3.40 3.00 2.40 N 
100 52 F 2 N N O,R N DIT 2.60 2.20 2.80 3.00 2.80 N 
  41.25   2.417         TAZ 3.12 2.76 2.13 1.58 1.14   
KEY TO MASTER CHART 
 
S.No – Serial Number 
AGE – Age 
SEX – Sex 
 M – Male 
 F – Female 
DU – Duration of Psoriasis 
EX – Exacerbating factors 
 ST – Stress 
 CO – Cold 
 ME – Menopause 
 N – Nil 
FH – Family History 
 Y – Yes 
 N – NO 
NI – Nail Involvement 
N – Nil 
PT – Pitting 
R – Ridging 
O – Onycholysis 
FS – Focal Sepsis 
Y – Yes 
 N – NO 
GR – Group 
 DIT –Dithranol 
 PLA – Placebo 
 STE – Steroid 
 TAZ – Tazarotene 
 PUV - PUVA 
PA – PASI 
 0    –  0 week 
 4    –  4th week 
 8    –  8th week 
 12  –  12th week 
 24  –  24th week 
AE – Adverse Effects 
Y – Yes 
 N – NO 
